MADRIGAL PHARMACEUTICALS, INC. (MDGL) Form 8-K — Jun 17, 2026
Madrigal Pharmaceuticals entered into a consulting agreement with Dr. Rebecca Taub, effective July 1, 2026, following her transition from employee to consultant. She will provide scientific guidance on MASH programs for an annual fee of $100,000 in addition to standard non-employee director compensation. Stockholders approved the 2026 Employee Stock Purchase Plan at the annual meeting, reserving 460,840 shares, while the Board adopted a Nonqualified Deferred Compensation Plan effective August 1, 2026.
Key figures
- Shares Outstanding
- 23,055,522
- Espp Shares Reserved
- 460,840
- Shares Present Voting
- 21,322,829
- Director Comp Limit Annual
- $750,000
- Stock Plan Shares Reserved
- 971,145
- Taub Consulting Fee Annual
- $100,000
Price after filing
Close on the filing date to close N calendar days later (from $499.86). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.